2024-03-29T05:47:45Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/502732016-02-17T07:17:26Zcom_10261_3284com_10261_1col_10261_3285
The PML-nuclear inclusion of human supraoptic neurons: A new compartment with SUMO-1- and ubiquitin-proteasome-associated domains
Villagra, Nuria T.
Navascués, Joaquín
Casafont, Íñigo
Val-Bernal, J. Fernando
Lafarga, Miguel
Berciano, María T.
It is well known that the cell nucleus is organized in structural and functional compartments involved in transcription, RNA processing and protein modifications such as conjugation with SUMO-1 and proteolysis. Promyelocytic leukaemia (PML) bodies are dynamic nuclear structures that concentrate PML protein, SUMO-1 and several sumoylated and non-sumoylated protein regulators of nuclear functions. PML bodies and their associated CBP has been involved in neuronal survival. By light and electron microscopy immunocytochemistry and in situ hybridization we reported the presence, in non-pathological conditions, of a large PML-nuclear inclusion (PML-NI) in human supraoptic neurons. This inclusion appears as a single nuclear structure composed of a capsule enriched in PML, SUMO-1 and CBP proteins and a central lattice of filaments immunoreactive for class III β-tubulin, ubiquitinated proteins and proteasomes. Furthermore, the PML-NI concentrates the SUMO-conjugating enzyme E2 (UBC9). The PML-NI may be considered a nuclear factory involved in sumoylation and proteolysis via ubiquitin-proteasome system, two nuclear pathways engaged in the control of the nucleoplasmic concentration of active transcriptional regulators. Interestingly, the structural and molecular organization of the PML-NI is related to the Marinesco bodies, age-associated ubiquitinated intranuclear inclusions, and to the intranuclear rodlets enriched in class III β-tubulin, which are nuclear structures markedly decreased in Alzheimer's disease. © 2005 Elsevier Inc. All rights reserved.
This study was supported by “Dirección General de Investigación Científica” from Spain (BFI2002-0454; BFU2005-01030), “Fondo de Investigación Sanitaria” from Spain (Red CIEN C03-C06) and Fundación Marqués de Valdecilla from Santander (API/05/04).
Peer Reviewed
2012-05-28T14:50:29Z
2012-05-28T14:50:29Z
2006
2012-05-28T14:50:29Z
artículo
http://purl.org/coar/resource_type/c_6501
doi: 10.1016/j.nbd.2005.07.003
issn: 0969-9961
Neurobiology of Disease 21(1): 181-193 (2006)
http://hdl.handle.net/10261/50273
10.1016/j.nbd.2005.07.003
en
none
Elsevier